MICHELLE DARNALL: Open Payments
NPI 1346642790 · ARKANSAS CITY, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$463 in 23 payments from 11 companies in 2025. Trend: 2023 $16 · 2024 $553 · 2025 $463
Food & beverage: $463
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $165 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $62 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $48 |
| Novo Nordisk Inc | 2 | $44 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Edwards Lifesciences Corporation | 1 | $19 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $18 |
Products named: AIRSUPRA, CAPLYTA, XIFAXAN, Wegovy, BREZTRI, GEMTESA, TRELEGY ELLIPTA, Auvelity.
Industry payments across KS — which companies pay providers there.
